Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses.

Granoff DM, Maslanka SE, Carlone GM, Plikaytis BD, Santos GF, Mokatrin A, Raff HV.

Clin Diagn Lab Immunol. 1998 Jul;5(4):479-85.

3.

Fluorophore-labeled carbohydrate analysis of immunoglobulin fusion proteins: Correlation of oligosaccharide content with in vivo clearance profile.

Flesher AR, Marzowski J, Wang WC, Raff HV.

Biotechnol Bioeng. 1995 Aug 5;47(3):405. No abstract available.

PMID:
18623415
4.
5.

Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides.

Häyrinen J, Jennings H, Raff HV, Rougon G, Hanai N, Gerardy-Schahn R, Finne J.

J Infect Dis. 1995 Jun;171(6):1481-90.

PMID:
7769282
6.

Characterization of biosynthetic IgG oligomers resulting from light chain variable domain duplication.

Roux KH, Shuford WW, Finley JW, Esselstyn J, Pankey S, Raff HV, Harris LJ.

Mol Immunol. 1994 Aug;31(12):933-42.

PMID:
8065376
8.

The stabilization of a human IgM monoclonal antibody with poly(vinylpyrrolidone).

Gombotz WR, Pankey SC, Phan D, Drager R, Donaldson K, Antonsen KP, Hoffman AS, Raff HV.

Pharm Res. 1994 May;11(5):624-32.

PMID:
8058628
9.

Monoclonal antibody homodimers: enhanced antitumor activity in nude mice.

Wolff EA, Schreiber GJ, Cosand WL, Raff HV.

Cancer Res. 1993 Jun 1;53(11):2560-5.

10.

Bacterial carbohydrates in neonatal sepsis: targets for immunotherapy.

Raff HV.

Springer Semin Immunopathol. 1993;15(2-3):173-81. Review. No abstract available.

PMID:
8256196
11.

Human monoclonal antibody homodimers. Effect of valency on in vitro and in vivo antibacterial activity.

Wolff EA, Esselstyn J, Maloney G, Raff HV.

J Immunol. 1992 Apr 15;148(8):2469-74.

PMID:
1560202
12.

Comparison of the opsonic and complement triggering activity of human monoclonal IgG1 and IgM antibody against group B streptococci.

Shyur SD, Raff HV, Bohnsack JF, Kelsey DK, Hill HR.

J Immunol. 1992 Mar 15;148(6):1879-84.

PMID:
1541826
13.

Monoclonal antibodies in the therapy of experimental neonatal group B streptococcal disease.

Hill HR, Kelsey DK, Gonzales LA, Raff HV.

Clin Immunol Immunopathol. 1992 Jan;62(1 Pt 2):S87-91.

PMID:
1728992
14.

The potential use of monoclonal antibodies as therapeutic modalities in neonatal infection.

Hill HR, Gonzales LA, Kelsey DK, Raff HV.

Clin Rev Allergy. 1992 Spring-Summer;10(1-2):29-38. No abstract available.

PMID:
1606522
15.
16.

Effect of light chain V region duplication on IgG oligomerization and in vivo efficacy.

Shuford W, Raff HV, Finley JW, Esselstyn J, Harris LJ.

Science. 1991 May 3;252(5006):724-7.

PMID:
1902593
17.

Comparative protective activity of human monoclonal and hyperimmune polyclonal antibody against group B streptococci.

Hill HR, Gonzales LA, Knappe WA, Fischer GW, Kelsey DK, Raff HV.

J Infect Dis. 1991 Apr;163(4):792-8.

PMID:
2010632
18.
19.

Comparison of functional activities between IgG1 and IgM class-switched human monoclonal antibodies reactive with group B streptococci or Escherichia coli K1.

Raff HV, Bradley C, Brady W, Donaldson K, Lipsich L, Maloney G, Shuford W, Walls M, Ward P, Wolff E, et al.

J Infect Dis. 1991 Feb;163(2):346-54.

PMID:
1988519
20.

Human monoclonal antibodies to group B streptococcus. Reactivity and in vivo protection against multiple serotypes.

Raff HV, Siscoe PJ, Wolff EA, Maloney G, Shuford W.

J Exp Med. 1988 Sep 1;168(3):905-17.

21.

Human monoclonal antibody with protective activity for Escherichia coli K1 and Neisseria meningitidis group B infections.

Raff HV, Devereux D, Shuford W, Abbott-Brown D, Maloney G.

J Infect Dis. 1988 Jan;157(1):118-26.

PMID:
3121759
22.
23.

Monoclonal antibodies: convergence of technology and application.

Raff HV.

Prog Clin Biol Res. 1986;211:247-63. No abstract available.

PMID:
3008195
24.

Leishmania tropica: differences in the antigenicity of promastigotes and amastigotes.

Sadick MD, Raff HV.

Cell Immunol. 1985 Apr 1;91(2):404-14.

PMID:
3873282
26.

Development of cellular immunity in cutaneous leishmaniasis due to Leishmania tropica.

Sadick MD, Locksley RM, Raff HV.

J Infect Dis. 1984 Jul;150(1):135-8.

PMID:
6611378
27.

Influence of dietary restriction and aging on natural killer cell activity in mice.

Weindruch R, Devens BH, Raff HV, Walford RL.

J Immunol. 1983 Feb;130(2):993-6.

PMID:
6600261
28.

Antigen-presenting capabilities of human monocytes correlates with their expression of HLA-DS, an Ia determinant distinct from HLA-DR.

Gonwa TA, Picker LJ, Raff HV, Goyert SM, Silver J, Stobo JD.

J Immunol. 1983 Feb;130(2):706-11.

PMID:
6184401
29.

The autologous mixed lymphocyte reaction in systemic lupus erythematosus.

Riccardi PJ, Hausman PB, Raff HV, Stobo JD.

Arthritis Rheum. 1982 Jul;25(7):820-3.

PMID:
6213238
31.

T cells and macrophages involved in the autologous mixed lymphocyte reaction are required for the response to conventional antigen.

Hausman PB, Raff HV, Gilbert RC, Picker LJ, Stobo JD.

J Immunol. 1980 Sep;125(3):1374-9. No abstract available.

PMID:
6447724
32.

Metabolic heterogeneity among human monocytes and its modulation by PGE2.

Picker LJ, Raff HV, Goldyne ME, Stobo JD.

J Immunol. 1980 Jun;124(6):2557-62. No abstract available.

PMID:
6246167
33.

Macrophage-T cell interactions in the Con A induction of human suppressive T cells.

Raff HV, Cochrum KC, Stobo JD.

J Immunol. 1978 Dec;121(6):2311-5.

PMID:
152792
34.
35.
36.

Supplemental Content

Support Center